Pteridines useful as hcv inhibitors and methods for the preparation thereof

Abstract

The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents.

1 - 21 . (canceled) 
     
     
         22 . A compound of the formula (VII): 
       
         
           
           
               
               
           
         
         or a salt, stereoisomeric form, or racemic mixture thereof, wherein 
         R 1  is hydrogen; 
         R 8  is hydrogen and R 9  is C 1-4 alkyl, —COR 6 , COOR 7 , or —CONR 4a R 4b ; 
         or 
         R 8  is C 1-6 alkyl or phenylC 1-4 alkyl and R 9  is hydrogen, C 1-4 alkyl, —COR 6 , COOR 7 , or —CONR 4a R 4b ; 
         R 6  is independently hydrogen, or C 1-4 alkyl; 
         each R 7  is independently hydrogen, or C 1-4 alkyl; and 
         each R 4a  and R 4b  is independently hydrogen, C 1-4 alkyl, 
       
     
     
         23 . The compound according to  claim 22 , wherein R 8  is hydrogen and R 9  is —C 1-4 alkyl, —COR 6 , —COOR 7 , or —CONR 4a R 4b . 
     
     
         24 . The compound according to  claim 23 , wherein R 9  is —CONR 4a R 4b . 
     
     
         25 . The compound according to  claim 22 , wherein R 8  is C 1-6 alkyl or phenylC 1-4 alkyl and R 9  is hydrogen, C 1-4 alkyl, —COR 6 , COOR 7 , or —CONR 4a R 4b . 
     
     
         26 . The compound according to  claim 25 , wherein R 8  is C 1-6 alkyl and R 9  is hydrogen. 
     
     
         27 . The compound according to  claim 25 , wherein R 8  is phenylC 1-4 alkyl and R 9  is hydrogen. 
     
     
         28 . The compound according to  claim 22  of the formula (VIII): 
       
         
           
           
               
               
           
         
       
     
     
         29 . The compound according to  claim 28 , wherein R 8  is hydrogen and R 9  is —C 1-4 alkyl, —COR 6 , —COOR 7 , or —CONR 4a R 4b . 
     
     
         30 . The compound according to  claim 28 , wherein R 8  is C 1-6 alkyl or phenylC 1-4 alkyl and R 9  is hydrogen, C 1-4 alkyl, —COR 6 , COOR 7 , or —CONR 4a R 4b . 
     
     
         31 . The compound according to  claim 30 , wherein R 8  is C 1-6 alkyl and R 9  is hydrogen. 
     
     
         32 , The compound according to  claim 22  that is 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
         33 . A pharmaceutical composition comprising a compound according to  claim 22  and a pharmaceutically acceptable excipient. 
     
     
         34 . The pharmaceutical composition according to  claim 33 , further comprising one or more other anti-hepatitis C virus agents.